2189.Hk
The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
Business. The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
The company maintains a market capitalization of HKD 470 million and a price-to-earnings ratio of 21.48, indicating a moderate valuation relative to its earnings. Its price-to-book ratio of 1.08 suggests that the market values the company's equity in line with its book value. The company's liquidity position is characterized by a current ratio of 1.03, which is slightly above 1, indicating a modest ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, the company reports a return on equity of 5.01% and a return on assets of 2.7%, which are below the industry median for healthcare facilities and services. This suggests that the company is not generating returns as efficiently as its peers. The operating margin, calculated as operating income divided by revenue, is 14.71%, which is a key metric for assessing operational efficiency in the healthcare sector.
The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the concentration of its revenue sources. However, the lack of detailed segment reporting may indicate a relatively undiversified business model. The company's revenue growth trajectory is not explicitly provided, but the absence of a clear growth pattern in the data suggests a stable or potentially stagnant revenue stream.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.76 indicates a moderate level of leverage, which is generally acceptable for a healthcare company but may increase financial risk if interest rates rise. The company's capital expenditure of HKD -19.78 million suggests a reduction in investment in physical assets, which could be a strategic decision to preserve cash or a sign of reduced growth opportunities.
Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The absence of recent significant events or disclosures may indicate a period of operational stability or a lack of material developments affecting the company's operations.
- The company's valuation is moderate, with a price-to-earnings ratio of 21.48 and a price-to-book ratio of 1.08.
- The company's return on equity and return on assets are below the industry median, indicating lower profitability.
- The company's liquidity position is modest, with a current ratio of 1.03 and a negative net cash position after debt.
- The company's capital expenditure is negative, suggesting a reduction in investment in physical assets.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 2189.HK Market data — financials · 2026-05-26